ESTA Establishment Labs Holdings Inc.

For growth investors, Establishment Labs Holdings (NASDAQ:ESTA) presents a compelling equity thesis: a medical aesthetics disruptor transitioning from cash-burning expansion to sustainable, profitable scale. Evaluating the company’s long-term fundamentals, such as its trajectory of multi-year revenue growth, operating cash flow generation, return on invested capital/ROIC, and ultimate free cash flow conversion, reveals a business at […]

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Discovery Fund”. A copy of the letter is available to download here. Baron Discovery Fund appreciated by 19.08% (Institutional Shares) in the quarter, underperforming the Russell 2000 Growth Index, which gained 25.71%. This lag was primarily due to a momentum-driven “AI […]

Establishment Labs Holdings has delivered a strong 122.5% return over the last year, yet current checks suggest the stock no longer looks obviously cheap, with the Discounted Cash Flow (DCF) intrinsic value estimate sitting close to the market price while market multiples lean expensive. Establishment Labs Holdings is up 122.5% over the past year, which puts extra focus on whether recent gains already reflect the company’s growth prospects. Recent company updates around global execution and...

Company raises full-year revenue guidance to $269-$271 million as minimally invasive platform gains traction and U.S. market expansion accelerates.

Establishment Labs (NASDAQ:ESTA) reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage. Revenue for the quarter totaled $67.5 million, while adjust

Establishment Labs (ESTA) delivered earnings and revenue surprises of -14.71% and +3.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD (LFMD) delivered earnings and revenue surprises of +20.00% and -3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?